Aliskiren: beyond blood pressure reduction

Bibliography

• Kearney PM, Whelton M, Reynolds K, Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
   PubMed Web of Science ®Google Scholar
• Ezzati M, Lopez AD, Rodgers AL, Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• Whelton PK, He J, Appel LJ, Primary prevention of hypertension: clinical and public health advisory from the National High Blood Pressure Education Programme. JAMA 2002;288:1882-88
   PubMed Web of Science ®Google Scholar
• Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010;105:30-5
   Google Scholar
• Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol 2010;105:21-9
   PubMedGoogle Scholar
• Sanoski CA. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension. Pharmacotherapy 2009;29:193-212
   PubMed Web of Science ®Google Scholar
• Beevers G, Lip GY, O'Brien E. ABC of hypertension: the pathophysiology of hypertension. Br Med J 2001;322:912-16
   PubMed Web of Science ®Google Scholar
• Oparil S, Zaman A, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med 2003;139:761-76
   PubMed Web of Science ®Google Scholar
• Steckelings UM, Rompe F, Kaschina E, The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol 2009;23:693-703
   PubMed Web of Science ®Google Scholar
• Reudelhuber TL. Renin. In: Oparil S, Weber MA, editors, Hypertension. 2nd edition. A companion to Brenner & Rector's The Kidney. Elsevier, Philadelphia; 2005. p. 89-94
   Google Scholar
• Delgado MC, Weder AB. Pathophysiology of hypertension. In: Oparil S, Weber MA, editors, Hypertension. 2nd edition. A companion to Brenner & Rector's The Kidney. Elsevier, Philadelphia; 2005. p. 29-38
   Google Scholar
• Weber MA. Angiotensin II receptor antagonists in the treatment of hypertension. Cardiol Rev 1997;5:712-80
   Google Scholar
• Schmieder RE. Angiotensin II-type 2 receptor: emerging target for cardiovascular protection. Am J Hypertens 2010;23:220
   PubMed Web of Science ®Google Scholar
• Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001;104:545-56
   PubMed Web of Science ®Google Scholar
• Riccioni G, Vitulano N, D'Orazio N, Aliskiren, the first approved renin inhibitor: clinical application and safety in the treatment of hypertension. Adv Ther 2009;26:700-10
   PubMed Web of Science ®Google Scholar
• Mancia G, De Baker G, Dominiczak A, Guidelines for the management of arterial hypertension: the Task Force for the Management of arterial hypertension of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Israili ZH, Velasco M, Bermudez V. Direct renin inhibitors as antihypertensive agents. Am J Ther 2010;17(3):237-54
   PubMed Web of Science ®Google Scholar
• Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 2008;51(5):519-28
   PubMed Web of Science ®Google Scholar
• Ramani GV, Uber PA, Mehra MR. Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc 2010;85:180-95
   PubMed Web of Science ®Google Scholar
• Seed A, Gardner R, McMurray J, Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure. Eur J Heart Fail 2007;9:1120-7
   PubMed Web of Science ®Google Scholar
• Stanton A, Jensen C, Nussberger J, Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137-43
   PubMed Web of Science ®Google Scholar
• Latini R, Masson S, Anand I, ; Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004;25:292-9
   PubMed Web of Science ®Google Scholar
• Solomon DS, Appelbaum E, Manning WJ, Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119:530-7
   PubMed Web of Science ®Google Scholar
• Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic disease. Am J Kidney 2004;43:1-290
   PubMed Web of Science ®Google Scholar
• Feldman DL, Jin L, Xuan H, Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen)27 rats. Hypertension 2008;52:130-6
   PubMed Web of Science ®Google Scholar
• Pimenta E, Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Vasc Health Risk Manag 2009;5:453-63
   PubMedGoogle Scholar
• Pilz B, Shagdarsuren E, Wellner M, Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005;46:569-76
   PubMed Web of Science ®Google Scholar
• Shagdarsuren E, Wellner M, Braesen JH, Complement activation in angiotensin II-induced organ damage. Circ Res 2005;97:716-24
   PubMed Web of Science ®Google Scholar
• Kelly DJ, Zhang Y, Moe G, Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropaty in rats. Diabetologia 2007;50:2398-404
   PubMed Web of Science ®Google Scholar
• Taal MV, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000;57:1803-17
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006;116:288-96
   PubMed Web of Science ®Google Scholar
• Peterson JC, Adler S, Burkart JM, Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-62
   PubMed Web of Science ®Google Scholar
• Lea J, Greene T, Hebert L, The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005;165:947-53
   PubMed Web of Science ®Google Scholar
• De Zeeuw D, Remuzzi G, Parving HH, Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20
   PubMed Web of Science ®Google Scholar
• Atkins RC, Briganti EM, Lewis JB, Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281-7
   PubMed Web of Science ®Google Scholar
• Toto RD. Lessons from the African-American Study of Kidney Disease and Hypertension: an update. Curr Hypertens Rep 2006;8:409-12
   PubMed Web of Science ®Google Scholar
• Persson F, Rossing P, Schjoedt KJ, Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008;73:1419-25
   PubMed Web of Science ®Google Scholar
• Parving HH, Persson F, Lewis JB, Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46
   PubMed Web of Science ®Google Scholar
• Tomas B. Renal protection by inhibition of the renin-angiotensin-aldosterone system. JRAAS 2009;1:1-8
   Google Scholar
• Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92
   PubMed Web of Science ®Google Scholar
• Charles CJ, Lainchbury JG, Nicholls MG, Adrenomedullin and the renin-angiotensin-aldosterone system. Regul Pept 2003;15:41-9
   Google Scholar
• Ross B, McKendy K, Giaid A. Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol 2010;298:1156-72
   PubMed Web of Science ®Google Scholar
• Takahashi K, Hirose T, Mori N, The renin-angiotensin system, adrenomedullins and urotensin II in the kidney: possible renoprotecion via the kidney peptide systems. Peptides 2009;30:1575-85
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• Mokdad AH, Ford ES, Bowman BA, Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9
   PubMed Web of Science ®Google Scholar
• Sowers JR, Epstein M, Frolich ED. Diabetes, hypertension, and cardiovascular disease. Anupdate. Hypertension 2001;37:1053-9
   PubMed Web of Science ®Google Scholar
• Gross JL, de Azevedo MJ, Silveiro SP, Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005;28:164-76
   PubMed Web of Science ®Google Scholar
• Anothaisintawee T, Rattanasiri S, Ingsathit A, Prevalence of chronic kidney disease: a systematic review and meta-analysis. Clin Nephrol 2009;71:244-54
   PubMed Web of Science ®Google Scholar
• Mann JF, Gerstein HC, Pogue J, Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001;134:629-36
   PubMed Web of Science ®Google Scholar
• Adler AI, Stevens RJ, Manley SE, Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-32
   PubMed Web of Science ®Google Scholar
• Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens 2004;17:16S-20
   PubMed Web of Science ®Google Scholar
• Rosenberg ME, Smith LJ, Correa-Rotter R, The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 1994;45:403-10
   PubMed Web of Science ®Google Scholar
• Wolf G. Angiotensin II is involved in the progression of renal disease: importance of non-hemodynamic mechanisms. Nephrologie 1998;19:451-6
   PubMedGoogle Scholar
• Kramkowski K, Mogielnicki A, Buczko W. The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol 2006;57:529-39
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Takai S. Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci 2006;100:391-7
   PubMed Web of Science ®Google Scholar
• Leckie BJ. Targeting the renin-angiotensin system: what's new? Curr Med Chem Cardiovasc Hematol Agents 2005;3:23-32
   PubMedGoogle Scholar
• Allan DR, Hui KY, Coletti C, Hollenberg NK. Renin vs angiotensin-converting enzyme inhibition in the rat: consequences for plasma and renal tissue angiotensin. J Pharmacol Exp Ther 1997;283:661-5
   PubMed Web of Science ®Google Scholar
• Nguyen G, Delarue F, Burckle C, Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-27
   PubMed Web of Science ®Google Scholar
• Nguyen G, Danser AH. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp Physiol 2008:93:557-63
   PubMed Web of Science ®Google Scholar
• Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005;465:1069-76
   Web of Science ®Google Scholar
• Danser AH. Novel drugs targeting hypertension: renin inhibitors. J Cardiovasc Pharmacol 2007;50:105-11
   PubMed Web of Science ®Google Scholar
• Deinum J, Ronn B, Mathiesen E, Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999;42:1006-10
   PubMed Web of Science ®Google Scholar
• Luetscher JA, Kraemer FB, Wilson DM, Increased plasma inactive renin in diabetes mellitus. A marker of micro-vascular complications. N Engl J Med 1985;312:1412-17
   PubMed Web of Science ®Google Scholar
• Danser AH, van den Dorpel MA, Deinum J, Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68:160-67
   PubMed Web of Science ®Google Scholar
• Ichihara A, Hayashi M, Kaneshiro Y, Inhibition of diabetic nephropathy by a decoy peptide corresponding to the “handle” region for nonproteolytic activation of prorenin. J Clin Invest 2004;114:1128-35
   PubMed Web of Science ®Google Scholar
• Sower JR. Insulin resistance and hypertension. Am J Physiol 2004;286:1597-602
   Google Scholar
• Krentz AJ, Clough G, Byrne CD. Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications. Diabetes Obes Metab 2007;9:781-91
   PubMed Web of Science ®Google Scholar
• Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension 1995;26:869-79
   PubMed Web of Science ®Google Scholar
• McGill JB. Improving microvascular outcomes in patients with diabetes through management of hypertension postgraduate medicine. Postgrad Med 2009;121(2):122-8
   PubMed Web of Science ®Google Scholar
• Davidson JA, Ciulla TA, McGill JB, How the diabetic eye loses vision. Endocrine 2007;32:107-16
   PubMed Web of Science ®Google Scholar
• Pache M, Kube T, Wolf S, Do angiographic data support a detailed classification of hypertensive fundus changes? J Hum Hypertens 2002;16:405-10
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003;26:2653-64
   PubMed Web of Science ®Google Scholar
• Silva KC, Pinto CC, Biswas SK, Hypertension increases retinal inflammation in experimental diabetes: a possible mechanism for aggravation of diabetic retinopathy by Hypertension. Curr Eye Res 2007;32:533-41
   PubMed Web of Science ®Google Scholar
• Phipps JA, Clermont AC, Sinha S, Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. Hypertension 2009;53:175-81
   PubMed Web of Science ®Google Scholar
• Adler AI, Stratton IM, Neil HA, Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412-19
   PubMed Web of Science ®Google Scholar
• Chaturvedi N, Porta M, Klein R, ; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372:1394-402
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53
   PubMed Web of Science ®Google Scholar
• Strawn WB, Chappell MC, Dean RH, Inhibition of early atherogenesis by losartan in monkeys with diet induced hypercholesterolemia. Circulation 2000;101:1586-93
   PubMed Web of Science ®Google Scholar
• Imanishi T, Tsujioka H, Ikejima H, Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008;52:563-72
   PubMed Web of Science ®Google Scholar
• Lu H, Rateri DL, Feldman DL, Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008;118:984-93
   PubMed Web of Science ®Google Scholar
• Parving HH, Barry M, Brenner J, Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663-71
   PubMed Web of Science ®Google Scholar
• Krum H. Role of renin in heart failure and therapeutic potential of direct renin inhibition. JRAAS 2008;9:177-80
   Google Scholar